# Pulmobiotics SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmobiotics-sl

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.pulmobio.com
- Total disclosed funding: $2.2M
- Latest round: Seed (Apr 14, 2020)
- Investors on record: 1

## About

Based in Barcelona, Spain, and founded in 2020 as a spin-off company from the Centre for Genomic Regulation, Barcelona, Pulmobiotics SL operates as a biotechnology company that offers a platform for treating respiratory diseases. In December 2022, the firm raised EUR 1.9 million in grant funding from the investor European Innovation Council. The firm as of December 2022 is led by its CEO, Claudio Santos.

The company through microbial engineering and synthetic biology offers a platform for the development of new treatments and vaccines for treating various respiratory diseases which cause severe illness and death, worldwide. The company’s platform is based on attenuated lung bacteria that expose antigens or deliver therapeutic agents in the lung in a controlled, local, and continuous manner. Pulmobiotics focus on vaccines, anti-microbial activity, tissue regeneration, and immune system modulation.

The company plans to utilize its December 2022 funding to conduct research and develop live biotherapeutics and medicines to improve the effectiveness of lung cancer treatment.

## Funding rounds

- Seed, Apr 14, 2020, $2.2M — Invivo Partners

## Investors

- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Seed